Caoyang Hu

Caoyang Hu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HGHong Guo
Hong Guo
LZLei Zhang
Lei Zhang
YSYuan Shao
Yuan Shao
KAKunyang An
Kunyang An
CHCaoyang Hu
Caoyang Hu
DWDongwen Wang
Dongwen Wang
Background: To systematically review and perform a meta-analysis on the predictive value of the primary Gleason grade (PGG) at the positive surgical margin (PSM), length of PSM, number of PSMs, and pathological stage of the primary tumor on biochemical recurrence (BCR) in patients with prostate cancer (PCa) after radical prostatectomy (RP). Methods: A systematic literature search was performed using electronic databases, including PubMed, EMBASE, Cochrane Library, and Web of Science, from January 1, 2005, to October 1, 2023. The protocol was pre-registered in PROSPERO. Subgroup analyses were performed according to the different treatments and study outcomes. Pooled hazard ratios with 95% confidence intervals were extracted from multivariate analyses, and a fixed or random effect model was used to pool the estimates. Subgroup analyses were performed to explore the reasons for the heterogeneity. Results: Thirty-one studies that included 50,028 patients with PCa were eligible for this meta-analysis. The results showed that, compared to PGG3, PGG4/5 was associated with a significantly increased risk of BCR. Compared with PSM ≤3 mm, PSM ≥3 mm was associated with a significantly increased risk of BCR. Compared with unifocal PSM, multifocal PSM (mF-PSM) was associated with a significantly increased risk of BCR. In addition, pT >2 was associated with a significantly increased risk of BCR compared to pT2. Notably, the findings were found to be reliable based on the sensitivity and subgroup analyses. Conclusions: PGG at the PSM, length of PSM, number of PSMs, and pathological stage of the primary tumor in patients with PCa were found to be associated with a significantly increased risk of BCR. Thus, patients with these factors should be treated differently in terms of receiving adjunct treatment and more frequent monitoring. Large-scale, well-designed prospective studies with longer follow-up periods are needed to validate the efficacy of these risk factors and their effects on patient responses to adjuvant and salvage therapies and other oncological outcomes.

26 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
HGHong Guo
Hong Guo
LZLei Zhang
Lei Zhang
YSYuan Shao
Yuan Shao
KAKunyang An
Kunyang An
CHCaoyang Hu
Caoyang Hu
DWDongwen Wang
Dongwen Wang
Background To systematically review and perform a meta-analysis on the predictive value of the primary Gleason grade (PGG) at the positive surgical margin (PSM), length of PSM, number of PSMs, and pathological stage of the primary tumor on biochemical recurrence (BCR) in patients with prostate cancer (PCa) after radical prostatectomy (RP). Methods A systematic literature search was performed using electronic databases, including PubMed, EMBASE, Cochrane Library, and Web of Science, from January 1, 2005, to October 1, 2023. The protocol was pre-registered in PROSPERO. Subgroup analyses were performed according to the different treatments and study outcomes. Pooled hazard ratios with 95% confidence intervals were extracted from multivariate analyses, and a fixed or random effect model was used to pool the estimates. Subgroup analyses were performed to explore the reasons for the heterogeneity. Results Thirty studies that included 46,572 patients with PCa were eligible for this meta-analysis. The results showed that, compared to PGG3, PGG4/5 was associated with a significantly increased risk of BCR. Compared with PSM ≤3 mm, PSM ≥3 mm was associated with a significantly increased risk of BCR. Compared with unifocal PSM, multifocal PSM (mF-PSM) was associated with a significantly increased risk of BCR. In addition, pT >2 was associated with a significantly increased risk of BCR compared to pT2. Notably, the findings were found to be reliable based on the sensitivity and subgroup analyses. Conclusions PGG at the PSM, length of PSM, number of PSMs, and pathological stage of the primary tumor in patients with PCa were found to be associated with a significantly increased risk of BCR. Thus, patients with these factors should be treated differently in terms of receiving adjunct treatment and more frequent monitoring. Large-scale, well-designed prospective studies with longer follow-up periods are needed to validate the efficacy of these risk factors and their effects on patient responses to adjuvant and salvage therapies and other oncological outcomes.

31 August 2024 in Urology
Verified
Journal Article
Open access
WZWei Zhang
Wei Zhang
FYFan Yang
Fan Yang
WLWeichao Li
Weichao Li
YMYuepeng Ma
Yuepeng Ma
ZMZhifang Ma
Zhifang Ma
CHCaoyang Hu
Caoyang Hu
To explore the association between drugs and urinary retention using the FDA Adverse Event Reporting System (FAERs) database and Mendelian randomization analysis, providing preliminary insights into the underlying mechanisms. Drug adverse reaction reports from the FAERs database from 2004 to 2023 were obtained, and Mendelian randomization analysis was conducted to further validate the causal relationship between drugs and urinary retention using genetic data provided by the IEU OpenGWAS project. We identified 78 drugs associated with urinary retention, including Mirabegron, Tiotropium, Quetiapine, and Amlodipine etc. Mendelian randomization analysis indicated genetic markers (SNPs rs10500326, rs4815689, and rs1216743) of Amlodipine were associated with an increased risk of urinary retention. Sensitivity analysis demonstrated the robustness and reliability of the results. This study identified various drugs associated with urinary retention, particularly Amlodipine. This finding provides new clues for further investigation into the mechanisms of drug effects on bladder function and offers important references for clinical practice. However, further randomized controlled trials are needed to validate these associations and explore deeper mechanisms.

18 September 2024 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
WZWei Zhang
Wei Zhang
XJXin Jiang
Xin Jiang
ZJZhisheng Jia
Zhisheng Jia
HTHua Tian
Hua Tian
RWRenjie Wang
Renjie Wang
CHCaoyang Hu
Caoyang Hu
BackgroundProstate cancer is one of the most common malignancies in men worldwide, and prostate-specific antigen (PSA) screening is widely used for its early detection. Drug use may affect PSA levels, but the effect for most drugs is currently unknown.MethodsThis study first investigated drugs related to PSA changes through the Food and Drug Administration Adverse Event Reporting System (FAERs) database, and then used a Mendelian randomization (MR) method to explore the causal relationship between specific drugs and PSA changes using a genome-wide association study (GWAS) data. The statistical analysis software SAS and R were used in the study.ResultsThrough analysis of the FAERs database, 22 drugs were found to be associated with an increase in PSA, and 14 drugs were associated with a decrease in PSA. MR analysis showed that the use of tamsulosin may lead to an increase in PSA. Heterogeneity test, horizontal pleiotropy test and leave-one-out Analysis verified the stability of the results. MR analyses for other drugs did not show statistical significance.ConclusionThis study provided a basis for better understanding the impact of medications on prostate health, helping to avoid overdiagnosis or underdiagnosis of high-risk patients. However, research still requires larger-scale validation and in-depth exploration.

8 December 2025 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
LZLei Zhang
Lei Zhang
KAKunyang An
Kunyang An
ZYZhe Yang
Zhe Yang
MYMei Yang
Mei Yang
HGHong Guo
Hong Guo
CHCaoyang Hu
Caoyang Hu
An activatable peptidyl fluorescent probe targeting GRP78 was developed by the integration of AI and molecular engineering. The probe successfully enabled high-contrast imaging of renal cell carcinoma in patient-derived tissue samples.